Expansion Momentum Aclarion is actively expanding its Nociscan platform across high-profile spine and neurosurgery networks, with Indiana first site rollout and ongoing provider-site growth, signaling a ready-to-scale sales motion for hospital systems and multi-site networks.

IP and Trust Signals Aclarion has a robust and expanding intellectual property portfolio with over 65 issued and pending patents worldwide, including AI-focused and MR spectroscopy process claims, which can bolster buyer confidence and justify partnerships with risk-conscious institutions.

Clinical and Reimbursement Progress Strong mid-year highlights show double-digit scan volume growth, reimbursement momentum in the UK, and ongoing CLARITY trial work, creating buying criteria around utilization, payer coverage, and real-world value demonstration for healthcare systems.

Strategic Partnerships Recent partnerships and site activations with major spine and neurosurgery networks (such as Goodman Campbell Brain & Spine at Ascension St. Vincent) point to a scalable channel through integrated delivery sites and referenceable centers for sales enablement.

Economic Readiness The company maintains a strong cash position with substantial cash reserves and a debt-free balance sheet, suggesting resilience in investments for expansion, clinical trials, and payer engagement activities that align with long sales cycles and capital budgeting in hospital procurement.